Chonbuk National University Hospital
Jeonju-si, Jeollabuk-do, Geonjiro, Deokjin-gu, 561-712, South Korea
NCT Number: NCT02004327
1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy
1. Primary
* AUClast, AUCinf, AUClast/D, AUCinf/D * Cmax, Cmax/D 2. Secondary
* Tmax, t1/2, CL/F, Vz/F 4. Safety
1. Adverse Event Monitoring 2. V/S, EKG, Laboratory Test, P/E
Looking for future studies?
Notify Me20 year–55 year
Male
Interventional
Phase 1
Jeonju-si, Jeollabuk-do, Geonjiro, Deokjin-gu, 561-712, South Korea
Healthy volunteers for clinical trials targeting drug administration date (1d) within 3 weeks from the (-21d ~-1d) in the interview, physical examination and laboratory tests , including through the screening is performed.
Through screening deems appropriate in this clinical trial is intended for the final subjects randomized to three groups to order .
The first phase one clinical trial subjects performed one day before (the -1 ) 18:00 Chonbuk National University Hospital, convened as a physical examination and perform hwalryeong signs .
One person to dinner , except for the drinking water should be fasting . One clinical trials (the first day) 20:00 subjects randomly assigned to groups according to the order in which the test is administered in a single oral medication .
The subjects for clinical trials with 240 mL water, medicines and swallow whole , chew before swallowing drugs should .
Blood according to the schedule after the clinical trial , including vital signs and physical examination is performed. The subjects that had a fixed schedule and is discharged on the morning of the second .
Is at least one week washout period . Since the two groups according to the order group and three creeping dose , except for the one the same tiles to proceed.
After a period of three clinical trials, three day period from taking drugs for clinical trials after 3-5 days to perform the post-study visit .
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
☞ body mass index (BMI) = weight (kg) / height (m) 2
Exclusion criteria
DW1029M300mg PO Once
Other names: DW1029M300mg 1 tablet
DW1029M300mg 2 tablets Once
Other names: DW1029M300mg 2 tablets
DW1029M300mg 4 tablets PO Once
Other names: DW1029M300mg 4 tablets
Time frame: 24 hours
Time frame: 24hours
Time frame: 24hours
Time frame: 24hours
Time frame: 24hours
Time frame: 24hours
Dong Wha Pharmaceutical Co. Ltd.
Industry
Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT01878045
Diabetes Complications, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial DetailsNCT05241522
Diabetes Complications, Diabetes Mellitus
San Diego, California, United States
View Trial DetailsNCT07672639
Chronic Disease, Chronic Kidney Disease
Beijing, Beijing Municipality, China
View Trial Details